All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
At the 60th American Society of Hematology Annual Meeting & Exposition, Chong Chyn Chua from The Alfred Hospital and Monash University, Melbourne, AU, gave a talk on the use of venetoclax in combination with intensive chemotherapy in fit elderly patients with acute myeloid leukemia (AML) .
The speaker presented updated data and molecular correlates of response from a phase Ib dose escalation study of venetoclax in combination with a dose-modified intensive chemotherapy regimen, in fit elderly AML patients who have not received prior induction chemotherapy. The primary objective of the study was to evaluate the optimal dose, safety and efficacy of venetoclax in combination with dose-modified intensive chemotherapy in older patients with AML. The secondary objectives were to evaluate the clinical response rates, overall survival (OS), duration response, time to hematopoietic recovery and rate of tumor lysis syndrome (TLS).
At data cut-off of 13 July 2018, 46 patients (median age = 72 years; range, 63–80) have been enrolled in this study. In order to mitigate the risk of hematologic toxicity and TLS, a 7-day venetoclax pre-phase, incorporating dose ramp-up to achieve steady state prior to commencing chemotherapy, was administered. Dose escalation of VEN began at 50 mg (cohort A), 100 mg (cohort B), 200 mg (cohort C), 400 mg (cohort D) and 600 mg (cohort E) on days 6–7 in combination with 5 +2 induction chemotherapy on days 1–5 (cytarabine [100 mg/m2/d IV on days 1–5] and idarubicin [12 mg/m2/d IV on days 2–3]) for one cycle. Patients who achieved complete remission (CR) were administered a consolidation consisting of venetoclax in combination with 2+1 chemotherapy (cytarabine [100 mg/m2/d IV on days 1–2] and idarubicin [12 mg/m2/d IV on day 1) for up to four cycles.
The speakers concluded by stating that “venetoclax up to 600mg in combination with 5+2 induction chemotherapy is tolerable and is associated with a high CR/CRi in patients with de novo AML.
Initial response rates were observed in NPM1 and IDH mutant AML, whereas responses were lower in patients with prior HMA exposure, adverse karyotype, secondary and TP53 mutant AML. Molecular determinants of relapse require further study.”
The impact of targeted treatment and immunotherapies on the role of hematopoietic stem cell transplantation in the treatment of blood cancers
Steven M. Bair and colleagues recently published a review in Cancer on the current role of HSCT in the...
ASH 2018 | Venetoclax-based therapies for patients with acute myeloid leukemia who are ineligible for intensive chemotherapy
At the 60th ASH Annual Meeting & Exposition, there were several talks focused on the use of venetoclax in combination with...
Subscribe to get the best content related to AML delivered to your inbox